Soleno Therapeutics, Inc.

DB:6XC Stock Report

Market Cap: €2.0b

Soleno Therapeutics Valuation

Is 6XC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6XC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€317.04
Fair Value
86.1% undervalued intrinsic discount
7
Number of Analysts

Below Fair Value: 6XC (€44.06) is trading below our estimate of fair value (€317.04)

Significantly Below Fair Value: 6XC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6XC?

Key metric: As 6XC is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 6XC. This is calculated by dividing 6XC's market cap by their current book value.
What is 6XC's PB Ratio?
PB Ratio7.6x
BookUS$264.70m
Market CapUS$2.02b

Price to Book Ratio vs Peers

How does 6XC's PB Ratio compare to its peers?

The above table shows the PB ratio for 6XC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
BIO3 Biotest
2.1x29.3%€1.4b
FYB Formycon
1.7x22.6%€988.8m
HPHA Heidelberg Pharma
3.3x-33.0%€118.4m
2INV 2invest
1.1xn/a€68.4m
6XC Soleno Therapeutics
7.6x58.4%€2.0b

Price-To-Book vs Peers: 6XC is expensive based on its Price-To-Book Ratio (7.6x) compared to the peer average (2.1x).

Price to Book Ratio vs Industry

How does 6XC's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
6XC 7.6xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 6XC is expensive based on its Price-To-Book Ratio (7.6x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 6XC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6XC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 6XC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6XC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€44.06
€72.01
+63.4%
10.8%€90.15€64.95n/a7
Jan ’26€41.92
€69.28
+65.3%
10.1%€86.77€62.51n/a8
Dec ’25€50.45
€69.28
+37.3%
10.1%€86.77€62.51n/a8
Nov ’25€50.65
€68.02
+34.3%
12.4%€85.98€56.39n/a7
Oct ’25€43.50
€65.05
+49.5%
13.3%€83.52€54.78n/a7
Sep ’25€41.54
€62.84
+51.3%
15.1%€83.15€52.75n/a7
Aug ’25€44.16
€62.37
+41.2%
17.0%€86.21€54.69n/a7
Jul ’25€37.34
€62.37
+67.0%
17.0%€86.21€54.69n/a7
Jun ’25€38.58
€62.37
+61.7%
17.0%€86.21€54.69n/a7
May ’25€34.78
€60.78
+74.8%
20.2%€86.74€47.57n/a6
Apr ’25€38.70
€59.26
+53.1%
21.2%€85.66€46.98n/a6
Mar ’25€44.00
€58.21
+32.3%
23.7%€85.71€40.55n/a6
Feb ’25€42.10
€49.25
+17.0%
13.3%€57.89€40.43n/a5
Jan ’25n/a
€45.90
0%
13.2%€53.63€39.99€41.924
Dec ’24n/a
€41.70
0%
17.6%€54.07€35.74€50.454
Nov ’24€22.20
€35.07
+58.0%
7.6%€36.97€31.28€50.653
Oct ’24€20.20
€35.64
+76.4%
5.0%€36.90€33.12€43.503
Sep ’24€4.44
€11.24
+153.1%
38.8%€17.31€7.29€41.543
Aug ’24€4.55
€11.21
+146.3%
38.8%€17.27€7.27€44.163
Jul ’24€3.79
€8.20
+116.3%
11.1%€9.11€7.29€37.342
Jun ’24€4.83
€8.20
+69.7%
11.1%€9.11€7.29€38.582
May ’24€2.88
€8.36
+190.4%
11.1%€9.29€7.44€34.782
Apr ’24€1.99
€8.36
+320.3%
11.1%€9.29€7.44€38.702
Mar ’24€1.88
€8.28
+340.6%
11.1%€9.20€7.36€44.002
Feb ’24€2.62
€8.28
+216.1%
11.1%€9.20€7.36€42.102
Jan ’24€1.78
€8.48
+376.2%
11.1%€9.42€7.54n/a2
Analyst Price Target
Consensus Narrative from 7 Analysts
€69.82
Fair Value
36.9% undervalued intrinsic discount
7
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 16:13
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Soleno Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC